Recently, the national medical insurance administration and the Ministry of human resources and social security issued the notice on bringing the negotiated drugs in 2019 into the category B of the national catalogue of drugs for basic medical insurance, work-related injury insurance and maternity insurance (medical insurance Fa [2019] No. 65), and officially announced the access results of negotiated drugs, with 70 new A total of 97 drugs with 27 renewal drugs entered the medical insurance catalogue through negotiation. So far, the adjustment of the national medical insurance drug catalogue in 2019 has been successfully completed, and the new catalogue will be launched on January 1, 2020.
A total of 150 drugs were involved in this negotiation, including 119 new negotiated drugs and 31 renewed negotiated drugs. 119 new negotiated drugs were negotiated into 70, and the price decreased by 60.7% on average. The average dosage of three kinds of HCV was over 85%, and the average rate of treatment for cancer and diabetes was about 65%. 31 renewed drugs were negotiated into 27, and the price decreased by 26.4% on average. After this round of adjustment, the list of drugs for national basic medical insurance, industrial injury insurance and maternity insurance in 2019 included 2709 drugs. Compared with the 2017 version, 218 drugs were transferred in and 154 drugs were transferred out, a net increase of 64.
This negotiation is the largest since the establishment of China's medical insurance system, and has achieved many results. First, the drug structure of the medical insurance catalogue was significantly optimized and the guarantee capacity was significantly improved. A number of drugs with high recognition, new listing and high clinical value were transferred to the catalogue, and the drug security ability of cancer, rare diseases, chronic diseases and children was significantly improved. Second, the cost of drugs has been significantly reduced. By giving full play to the role of "strategic buyer" of the medical insurance department, the drug cost has been greatly reduced by exchanging quantity for price. Several world-famous "noble drugs" have issued "civilian prices", and imported drugs have basically given the lowest price in the world. It is conservatively estimated that through negotiated price reduction and medical insurance reimbursement, the personal burden of patients will be reduced to less than 20% and individual drugs to less than 5%. Third, it highlights the orientation of encouraging innovation. Eight of the 12 major domestic innovative drugs were negotiated. Most of the drugs successfully negotiated in this negotiation are new drugs listed in recent years, many of which are newly listed in 2018. These newly marketed drugs were quickly included in the catalogue, releasing a clear signal to support innovation. Fourth, progress has been made in exploring ways to adjust the catalogue of Medicare drugs in line with China's reality. In order to help guide enterprises to reduce prices significantly, we actively explored ways such as introducing competitive negotiation and giving play to the role of pharmacoeconomics evaluation, which greatly improved the scientificity, standardization and effectiveness of the negotiation.
Next, the National Medical Insurance Bureau will work with relevant departments to guide all localities to implement the negotiated drug catalogue, strengthen policy publicity and interpretation, do a good job in drug use connection and guarantee, and ensure that all localities will open the new catalogue on January 1, 2020 to benefit the broad masses of the people as soon as possible.